BR112012033022A2 - tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral - Google Patents

tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral

Info

Publication number
BR112012033022A2
BR112012033022A2 BR112012033022A BR112012033022A BR112012033022A2 BR 112012033022 A2 BR112012033022 A2 BR 112012033022A2 BR 112012033022 A BR112012033022 A BR 112012033022A BR 112012033022 A BR112012033022 A BR 112012033022A BR 112012033022 A2 BR112012033022 A2 BR 112012033022A2
Authority
BR
Brazil
Prior art keywords
hydroxychloroquine
virus
combination
antiviral agent
treating disease
Prior art date
Application number
BR112012033022A
Other languages
English (en)
Portuguese (pt)
Inventor
Philippe Halfon
Original Assignee
Genosciense Pharma Sas
Panmed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genosciense Pharma Sas, Panmed Ltd filed Critical Genosciense Pharma Sas
Publication of BR112012033022A2 publication Critical patent/BR112012033022A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012033022A 2010-06-24 2011-06-23 tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral BR112012033022A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35801410P 2010-06-24 2010-06-24
PCT/IB2011/052762 WO2011161644A1 (en) 2010-06-24 2011-06-23 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent

Publications (1)

Publication Number Publication Date
BR112012033022A2 true BR112012033022A2 (pt) 2016-12-20

Family

ID=44630083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012033022A BR112012033022A2 (pt) 2010-06-24 2011-06-23 tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral

Country Status (10)

Country Link
US (2) US8987302B2 (https=)
EP (1) EP2585065A1 (https=)
JP (1) JP2013529627A (https=)
CN (1) CN103096891A (https=)
AU (1) AU2011268498A1 (https=)
BR (1) BR112012033022A2 (https=)
CA (1) CA2803093A1 (https=)
IN (1) IN2012MN02896A (https=)
MX (1) MX2013000242A (https=)
WO (1) WO2011161644A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
CN103145811B (zh) * 2013-03-15 2014-05-07 深圳翰宇药业股份有限公司 一种合成阿拉泊韦的方法
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US20230139565A1 (en) * 2020-04-20 2023-05-04 Glanis Pharmaceuticals, Inc. Oral delivery system comprising hydroxychloroquine and/or chloroquine
US20230149515A1 (en) * 2020-04-29 2023-05-18 The Regents Of The University Of Michigan Inhibition of sars-cov-2 viral entry through oral administration of lactoferrin and uses thereof
JP7477152B2 (ja) 2020-05-12 2024-05-01 国立大学法人 宮崎大学 Ｈｔｌｖ－１関連疾患の発症予防、進展抑制または治療のための剤
JP2024504728A (ja) 2021-01-26 2024-02-01 サイトケアズ （シャンハイ） インコーポレイテッド キメラ抗原受容体（ｃａｒ）構築物およびｃａｒ構築物を発現するｎｋ細胞
CN114796126B (zh) * 2022-04-02 2023-04-18 复旦大学附属中山医院青浦分院(上海市青浦区中心医院) 关节腔注射用硫酸羟氯喹缓释微球及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5314894A (en) 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
ITBO20020416A1 (it) * 2002-06-28 2003-12-29 Valpharma Sa Uso della clorochina, idrossi-clorochina e derivati 4 amino-chinolinici per l'ottenimento di un farmaco per la terapia anti retrovirale atti
CA2676567A1 (en) 2003-02-21 2005-03-31 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US7671017B2 (en) 2004-07-14 2010-03-02 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
WO2006109196A2 (en) 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
BRPI0614205A2 (pt) 2005-08-01 2016-11-22 Merck & Co Inc composto, composição farmacêutica, e, uso de composto
WO2010101649A2 (en) * 2009-03-05 2010-09-10 Pablo Gastaminza Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
AU2011209051B2 (en) 2010-01-27 2015-01-15 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus

Also Published As

Publication number Publication date
US8575195B2 (en) 2013-11-05
WO2011161644A1 (en) 2011-12-29
IN2012MN02896A (https=) 2015-06-12
JP2013529627A (ja) 2013-07-22
US20130121965A1 (en) 2013-05-16
CA2803093A1 (en) 2011-12-29
US8987302B2 (en) 2015-03-24
EP2585065A1 (en) 2013-05-01
CN103096891A (zh) 2013-05-08
AU2011268498A1 (en) 2013-01-31
MX2013000242A (es) 2014-04-14
US20130202556A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
BR112012033022A2 (pt) tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral
CY2024017I1 (el) Συνδυασμοι δολουτεγραβιρης και λαμιβουδινης για την αγωγη λοιμωξης απο hiv
UY34851A (es) Inhibidores macrocíclicos de virus flaviviridae
HUE052856T2 (hu) Eljárások és gyógyászati készítmények Hepatitis B vírus fertõzés kezelésére
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
CY2017019I2 (el) Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
GEP20146134B (en) Inhibitors of hepatitis c virus replication
EP3325097A4 (en) COMPOSITIONS AND AGENTS AGAINST HEPATITIS B VIRUS AND USES THEREOF
CL2015000482A1 (es) Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b
HUE053946T2 (hu) 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
GT201200257A (es) Composiciones sólidas
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
IL228906A0 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
DK3311824T3 (da) Cd47 målrettede terapier til behandlingen af infektionssygdomme
BR112012024661A2 (pt) composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
BR112012008048A2 (pt) dispositivos eletrocrômicos, montagens que incorporam dispositivos eletrocrômicos, e/ou métodos de fabricação dos mesmos
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
GB2548034B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
GB201303868D0 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
BR112015012778A2 (pt) estrutura de suporte de componente de escapamento
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112014009322A2 (pt) inibidor de catecol-o-metiltransferase (comt), combinação do mesmo com um agente terapêutico adicional e agente terapêutico
BRPI1011071B8 (pt) uso de um heptapeptídeo para estimular a função genital, sexual ou reprodutiva em um mamífero

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]